Save over 35% with Rukobia from Europe
Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine
Marketing Authorisation Holder for Europe
ViiV Healthcare BV
Van Asch van Wijckstraat 55H
3811 LP Amersfoort
Netherlands
Manufacturer in Europe
GlaxoSmithKline Manufacturing S.P.A
Strada Provinciale Asolana, 90
San Polo di Torrile
Parma, 43056
Italy
Information about Rukobia (Fostemsavir)
Rukobia (fostemsavir) is a medication used in the treatment of HIV (Human Immunodeficiency Virus). It is an antiviral drug that belongs to a class called attachment inhibitors. Rukobia works by blocking HIV from entering healthy cells, specifically by inhibiting the interaction between the virus and the CD4 receptors on the surface of the immune cells, a key step in the virus's ability to replicate and spread.
Product Highlights
- Rukobia is primarily indicated for the treatment of HIV-1 infection in adults who have experienced virologic failure (i.e., resistance or poor response) to their current antiretroviral regimen.
- It is typically prescribed as part of a combination therapy alongside other antiretroviral drugs.
Key Ingredient
Key Benefits
- Rukobia is often used when other antiretroviral drugs have become ineffective due to HIV resistance.
- It prevents HIV from binding to and entering immune cells, effectively limiting viral replication.
- It is usually used in combination with other HIV treatments to achieve a more potent antiretroviral regimen.
- Fostemsavir has a relatively low potential for interactions with other HIV medications, which makes it a good option for those with complex treatment regimens.
Direction of Use
- The typical dosage of Rukobia is 600 mg once daily, taken orally, with or without food.
- The tablet should be swallowed whole. It’s essential to follow the prescribed dosing regimen, and missed doses should be taken as soon as possible, unless it’s close to the time for the next dose.
- Fostemsavir is generally used in combination with other HIV medications, so the overall treatment plan may involve taking multiple drugs.
Safety Concerns
- Using Rukobia alone, without appropriate combination therapy, could lead to the development of drug-resistant HIV strains.
- As with other HIV treatments, there is a risk of IRIS, where the immune system starts to respond to previously undiagnosed infections when HIV suppression begins.
- Patients with liver issues should be monitored closely, as there could be an increased risk of liver toxicity.
- Rukobia may cause a lengthening of the QT interval (a type of heart rhythm disturbance), so people with heart conditions should be cautious.
Avoid Rukobia (Fostemsavir) If
- If you have a known hypersensitivity (allergic) reaction to fostemsavir or any other components of the medication, Rukobia should not be used.
- People with severe liver impairment (e.g., cirrhosis) should avoid this medication or use it with caution.
- Due to its potential to prolong the QT interval, patients with a history of arrhythmias or those who take other medications that can cause QT prolongation should avoid using Rukobia unless advised by a doctor.
